€7.75
Your prediction
Aurinia Pharmaceuticals Inc. Stock
Pros and Cons of Aurinia Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Aurinia Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. | 0.610% | 21.963% | 9.399% | 51.111% | -11.243% | -32.988% | -40.369% |
| Promis Neurosciences Inc. | -2.960% | -9.140% | -23.182% | -81.222% | -60.000% | -95.015% | -95.752% |
| Resverlogix Corp | 24.070% | 10.000% | 34.146% | 1.852% | 1.852% | -83.232% | -94.124% |
| Enwave Corporation | -7.300% | 14.530% | 11.667% | 87.413% | 94.203% | -41.612% | -60.990% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon a first glance at the financials of Aurinia Pharma, a company within the Biotechnology & Medical Research industry, it is clear that they have experienced fluctuations within their financial performance over the past few years. The company's balance sheet, cash flow, and income statement show some promising elements, as well as a few areas of concern.
*Pros: *
Growing Total Assets and Stockholder Equity: Over the past three years, Aurinia Pharma has seen a steady growth in their total assets, from $463.66 million in 2020 to $470.86 million in 2022. This growth signifies an expanding company, which is a positive sign for investors. Additionally, the total stockholder equity has increased from $407.75 million in 2020 to $405.43 million in 2022, highlighting a robust financial foundation for the company.
Comments
News
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who